VRNA (Verona Pharma) Receivables Turnover : 1.63 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Verona Pharma's Revenue for the three months ended in Mar. 2025 was $76.3 Mil. Verona Pharma's average Accounts Receivable for the three months ended in Mar. 2025 was $46.8 Mil. Hence, Verona Pharma's Receivables Turnover for the three months ended in Mar. 2025 was 1.63.

Verona Pharma Receivables Turnover Historical Data

The historical data trend for Verona Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Receivables Turnover Chart

Verona Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

1.34

Verona Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Receivables Turnover	Get a 7-Day Free Trial															-	-	0.81	1.91	1.63

Competitive Comparison of Verona Pharma's Receivables Turnover

For the Biotechnology subindustry, Verona Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verona Pharma's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Verona Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Verona Pharma's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	42.279	/ (	(0	+	31.496)	/	1 )
=	42.279	/	31.496
=	1.34

Verona Pharma's Receivables Turnover for the quarter that ended in Mar. 2025 is calculated as

	Receivables Turnover (Q: Mar. 2025 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2025 )	/ (	(Accounts Receivable (Q: Dec. 2024 )	+	Accounts Receivable (Q: Mar. 2025 ))	/	count )
=	76.256	/ (	(31.496	+	62.159)	/	2 )
=	76.256	/	46.8275
=	1.63

Verona Pharma (NAS:VRNA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Verona Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Verona Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

I9SA:Germany I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Executives

Kathleen A. Rickard	officer: Chief Medical Officer	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn	officer: Chief Financial Officer	6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli	director, officer: President and CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David R Ebsworth	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Christina Ackermann	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Claire Poll	officer: General Counsel	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc	10 percent owner	C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc	10 percent owner	730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik	10 percent owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE